DNA mismatch repair enzymes: Genetic defects and autoimmunity

Clinica Chimica Acta

Volumn 442, Issue , 2015, Pages 102-109

  Muro, Yoshinao ^a   Sugiura, Kazumitsu ^a   Mimori, Tsuneyo ^b   Akiyama, Masashi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoantibody; DNA mismatch repair; Idiopathic inflammatory myopathy; MLH1; PMS1

Indexed keywords

AUTOANTIBODY; MISMATCH REPAIR ENZYME; MISMATCH REPAIR PROTEIN PMS2; NUCLEAR PROTEIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN PMS1; UNCLASSIFIED DRUG; DNA LIGASE;

ANTIBODY RESPONSE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DEGENERATIVE DISEASE; ENZYME ACTIVITY; ENZYME STRUCTURE; GENE MUTATION; GENETIC DISORDER; HEMATOLOGIC DISEASE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; MISMATCH REPAIR; MYOSITIS; NEOPLASM; REVIEW; TRINUCLEOTIDE REPEAT; ANIMAL; DISEASES; GENETICS; IMMUNOLOGY;

BACTERIA (MICROORGANISMS);

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; DISEASE; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; HUMANS;

EID: 84921957599     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.01.014     Document Type: Review

References (61)

1. von Mühlen C.A., Tan E.M. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995, 24:323-358.
2. Mahler M., Pierangeli S., Meroni P.L., Fritzler M.J. Autoantibodies in systemic autoimmune disorders. J Immunol Res 2014, 2014:263091.
3. Casciola-Rosen L., Mammen A.L. Myositis autoantibodies. Curr Opin Rheumatol 2012, 24:602-608.
4. Tansley S.L., Betteridge Z.E., McHugh N.J. The diagnostic utility of autoantibodies in adult and juvenile myositis. Curr Opin Rheumatol 2013, 25:772-777.
5. Casciola-Rosen L.A., Pluta A.F., Plotz P.H., et al. The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. Arthritis Rheum 2001, 44:389-396.
6. Okada T., Noji S., Goto Y., et al. Immune responses to DNA mismatch repair enzymes hMSH2 and hPMS1 in patients with pancreatic cancer, dermatomyositis and polymyositis. Int J Cancer 2005, 116:925-933.
7. Muro Y., Nakashima R., Hosono Y., Sugiura K., Mimori T., Akiyama M. Autoantibodies to DNA mismatch repair enzymes in polymyositis/dermatomyositis and other autoimmune diseases: a possible marker of favorable prognosis. Arthritis Rheumatol 2014, 66:3457-3462.
8. Satoh M., Ceribelli A., Chan E.K. Common pathways of autoimmune inflammatory myopathies and genetic neuromuscular disorders. Clin Rev Allergy Immunol 2012, 42:16-25.
9. Iyer R.R., Pluciennik A., Burdett V., Modrich P.L. DNA mismatch repair: functions and mechanisms. Chem Rev 2006, 106:302-323.
10. Hsieh P., Yamane K. DNA mismatch repair: molecular mechanism, cancer, and ageing. Mech Ageing Dev 2008, 129:391-407.
11. Larrea A.A., Lujan S.A., Kunkel T.A. SnapShot: DNA mismatch repair. Cell 2010, 141:730.e1.
12. Räschle M., Marra G., Nyström-Lahti M., Schär P., Jiricny J. Identification of hMutLbeta, a heterodimer of hMLH1 and hPMS1. J Biol Chem 1999, 274:32368-32375.
13. Cannavo E., Marra G., Sabates-Bellver J., et al. Expression of the MutL homologue hMLH3 in human cells and its role in DNA mismatch repair. Cancer Res 2005, 65:10759-10766.
14. Lipkin S.M., Moens P.B., Wang V., et al. Meiotic arrest and aneuploidy in MLH3-deficient mice. Nat Genet 2002, 31:385-390.
15. Kunkel T.A., Erie D.A. DNA mismatch repair. Annu Rev Biochem 2005, 74:681-710.
16. Jiricny J. MutLα: at the cutting edge of mismatch repair. Cell 2006, 126:239-241.
17. Modrich P. Mechanisms in eukaryotic mismatch repair. J Biol Chem 2006, 281:30305-30309.
18. Hampel H., Frankel W.L., Martin E., et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008, 26:5783-5788.
19. Lynch H.T., Lynch P.M., Lanspa S.J., Snyder C.L., Lynch J.F., Boland C.R. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009, 76:1-18.
20. Barnetson R.A., Tenesa A., Farrington S.M., et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006, 354:2751-2763.
21. Hampel H., Frankel W.L., Martin E., et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005, 352:1851-1860.
22. Palomaki G.E., McClain M.R., Melillo S., Hampel H.L., Thibodeau S.N. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009, 11:42-65.
23. Tutlewska K., Lubinski J., Kurzawski G. Germline deletions in the EPCAM gene as a cause of Lynch syndrome - literature review. Hered Cancer Clin Pract 2013, 11:9.
24. Ligtenberg M.J., Kuiper R.P., Chan T.L., et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet 2009, 41:112-117.
25. Vasen H.F., Mecklin J.P., Khan P.M., Lynch H.T. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991, 34:424-425.
26. Vasen H.F., Watson P., Mecklin J.P., Lynch H.T. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999, 116:1453-1456.
27. Boland C.R., Shike M. Report from the Jerusalem workshop on Lynch syndrome-hereditary nonpolyposis colorectal cancer. Gastroenterology 2010, 138:2197.e1-7.
28. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009, 11:35-41.
29. Ponti G., Ponz de Leon M. Muir-Torre syndrome. Lancet Oncol 2005, 6:980-987.
30. Mangold E., Rahner N., Friedrichs N., et al. MSH6 mutation in Muir-Torre syndrome: could this be a rare finding?. Br J Dermatol 2007, 156:158-162.
31. South C.D., Hampel H., Comeras I., Westman J.A., Frankel W.L., de la Chapelle A. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst 2008, 100:277-281.
32. Ponti G., Losi L., Pedroni M., et al. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas. J Invest Dermatol 2006, 126:2302-2307.
33. Wimmer K., Kratz C.P., Vasen H.F., et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'care for CMMRD' (C4CMMRD). J Med Genet 2014, 51:355-365.
34. Péron S., Metin A., Gardès P., et al. Human PMS2 deficiency is associated with impaired immunoglobulin class switch recombination. J Exp Med 2008, 205:2465-2472.
35. Plaschke J., Linnebacher M., Kloor M., et al. Compound heterozygosity for two MSH6 mutations in a patient with early onset of HNPCC-associated cancers, but without hematological malignancy and brain tumor. Eur J Hum Genet 2006, 14:561-566.
36. Rahner N., Höefler G., Högenauer C., et al. Compound heterozygosity for two MSH6 mutations in a patient with early onset colorectal cancer, vitiligo and systemic lupus erythematosus. Am J Med Genet A 2008, 146A:1314-1319.
37. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
38. Walker F.O. Huntington's disease. Lancet 2007, 369:218-228.
39. López Castel A., Cleary J.D., Pearson C.E. Repeat instability as the basis for human diseases and as a potential target for therapy. Nat Rev Mol Cell Biol 2010, 11:165-170.
40. Kalsotra A., Xiao X., Ward A.J., et al. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci U S A 2008, 105:20333-20338.
41. Kuyumcu-Martinez N.M., Wang G.S., Cooper T.A. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell 2007, 28:68-78.
42. Machuca-Tzili L., Brook D., Hilton-Jones D. Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve 2005, 32:1-18.
43. Manley K., Shirley T.L., Flaherty L., Messer A. Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice. Nat Genet 1999, 23:471-473.
44. Wheeler V.C., Gutekunst C.A., Vrbanac V., et al. Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum Mol Genet 2002, 11:633-640.
45. Savouret C., Brisson E., Essers J., et al. CTG repeat instability and size variation timing in DNA repair-deficient mice. EMBO J 2003, 22:2264-2273.
46. Foiry L., Dong L., Savouret C., et al. Msh3 is a limiting factor in the formation of intergenerational CTG expansions in DM1 transgenic mice. Hum Genet 2006, 119:520-526.
47. Gomes-Pereira M., Fortune M.T., Ingram L., McAbney J.P., Monckton D.G. Pms2 is a genetic enhancer of trinucleotide CAG.CTG repeat somatic mosaicism: implications for the mechanism of triplet repeat expansion. Hum Mol Genet 2004, 13:1815-1825.
48. Slean M.M., Panigrahi G.B., Ranum L.P., Pearson C.E. Mutagenic roles of DNA "repair" proteins in antibody diversity and disease-associated trinucleotide repeat instability. DNA Repair (Amst) 2008, 7:1135-1154.
49. n-hairpin DNA binds to Msh2-Msh3 and changes properties of mismatch recognition. Nat Struct Mol Biol 2005, 12:663-670.
50. van den Broek W.J., Nelen M.R., Wansink D.G., et al. Somatic expansion behaviour of the (CTG)n repeat in myotonic dystrophy knock-in mice is differentially affected by Msh3 and Msh6 mismatch-repair proteins. Hum Mol Genet 2002, 11:191-198.
51. Tian L., Hou C., Tian K., Holcomb N.C., Gu L., Li G.M. Mismatch recognition protein MutSbeta does not hijack (CAG)n hairpin repair in vitro. J Biol Chem 2009, 284:20452-20456.
52. Panigrahi G.B., Lau R., Montgomery S.E., Leonard M.R., Pearson C.E. Slipped (CTG)·(CAG) repeats can be correctly repaired, escape repair or undergo error-prone repair. Nat Struct Mol Biol 2005, 12:654-662.
53. McMurray C.T. Mechanisms of trinucleotide repeat instability during human development. Nat Rev Genet 2010, 11:786-799.
54. Kim J.C., Mirkin S.M. The balancing act of DNA repeat expansions. Curr Opin Genet Dev 2013, 23:280-288.
55. Marsh J.C., Ball S.E., Cavenagh J., et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009, 147:43-70.
56. Rosenfeld S., Follmann D., Nunez O., Young N.S. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003, 289:1130-1135.
57. Hirano N., Butler M.O., Von Bergwelt-Baildon M.S., et al. Autoantibodies frequently detected in patients with aplastic anemia. Blood 2003, 102:4567-4575.
58. Hirano N., Butler M.O., Guinan E.C., Nadler L.M., Kojima S. Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients. Br J Haematol 2005, 128:221-223.
59. Tomé S., Manley K., Simard J.P., et al. MSH3 polymorphisms and protein levels affect CAG repeat instability in Huntington's disease mice. PLoS Genet 2013, 9:e1003280.
60. Panigrahi G.B., Slean M.M., Simard J.P., Pearson C.E. Human mismatch repair protein hMutLα is required to repair short slipped-DNAs of trinucleotide repeats. J Biol Chem 2012, 287:41844-41850.
61. Kondo E., Horii A., Fukushige S. The interacting domains of three MutL heterodimers in man: hMLH1 interacts with 36 homologous amino acid residues within hMH3, hPMS1 and hPMS2. Nucleic Acids Res 2001, 29:1695-1702.